2017年5月22日 · PD-L1 is a protein that allows some cells to escape an attack by the immune system. Extending from the cancer cell surface, PD-L1 interacts with a protein called PD-1 on important immune system cells called T cells.

PD-L1 testing is used to look for the PD-L1 protein on cancer cells in a sample of tumor tissue. The test also measures the amount of PD-L1 in the tissue. This information helps find out if immunotherapy medicines could help control your cancer.

Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis.

2020年3月1日 · Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit …

Therapeutic antibody-mediated blockade of PD-1 or one of its ligands, PD-L1, removes the suppressive effects of PD-L1 on cytotoxic T-cells with restoration of host immunity against the tumour.

PD-L1 is an immunoinhibitory molecule that suppresses the activation of T cells, leading to the progression of tumors. Overexpression of PD-L1 in cancers such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, ...

Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker. Methods.

2016年5月16日 · PD-L1 works like a “stop sign” to inactivate T cells. 1. PD-L1 works by attaching to receptors on T cells called PD-1 and B7.1. Both PD-1 and B7.1 can inactivate T cells. 2. …

Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer.

2022年2月7日 · We describe the roles of the diverse post-translational modifications of PD-L1, including phosphorylation, palmitoylation, glycosylation, acetylation and ubiquitination.